Modern Inhalational Anesthetics for Refractory Status Epilepticus

Canadian Journal of Neurological Sciences

Volumn 42, Issue 2, 2015, Pages 106-115

  Zeiler, Frederick A ^a,b   Zeiler, Kaitlin J ^b   Teitelbaum, Jeanne ^b   Gillman, Lawrence M ^a   West, Michael ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Inhalational anesthetics; status epilepticus; volatile anesthetics

Indexed keywords

ANESTHETIC GAS; DESFLURANE; HALOTHANE; HYPERTENSIVE FACTOR; INHALATION ANESTHETIC AGENT; ISOFLURANE; KETAMINE; XENON;

ARTICLE; BIOSIS; CARDIOVASCULAR EFFECT; COCHRANE LIBRARY; DATA BASE; DISABILITY; DISEASE CONTROL; DRUG EFFICACY; EMBASE; EPILEPTIC DISCHARGE; EPILEPTIC STATE; HUMAN; HYPOTENSION; KIDNEY DISEASE; MEDLINE; PERSISTENT VEGETATIVE STATE; PRIORITY JOURNAL; REFRACTORY STATUS EPILEPTICUS; SCOPUS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; ADULT; CHILD; DRUG RESISTANT EPILEPSY; EVIDENCE BASED MEDICINE; META ANALYSIS; PRACTICE GUIDELINE; STATUS EPILEPTICUS; TREATMENT OUTCOME;

ADULT; ANESTHETICS, INHALATION; CHILD; DRUG RESISTANT EPILEPSY; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84954311975     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/cjn.2014.121     Document Type: Article

References (49)

1. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17: 3-23.
2. Claassan J, Silbergleit R, Weingart SD, Smith WD. Emergency neurological life support. Neurocrit Care. 2012;17:S73-8.
3. Hunter G, Young B. Status epilepticus: a review, with emphasis on refractory cases. Can J Neurol Sci. 2012;39:157-69.
4. Deeb TZ, Maguire J, Moss SJ. Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia. 2012;53(Suppl. 9):79-88.
5. Feng HJ, Mathews GC, Kao C, Macdonald RL. Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol. 2008;99:1285-93.
6. Loscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia. 2007;48(Suppl. 8):74-7.
7. Loscher W, Potscha H. Drug resistance in brain disease and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591-602.
8. Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci. 2002;22:5833-9.
9. Fujikawa DG. Prolonged seizure and cellular injury: understanding the connection. Epilepsy Behav. 2005;7(Suppl. 3):S3-11.
10. Alexopoulos A, Lachwani DK, Gupta A, et al. Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis. Neurology. 2005;64:567-70.
11. Azzopardi D, Roberston NJ, Kapetanakis A, et al. Anticonvulsant effect of xenon on neonatal asphyxial seizures. Arch Dis Child Fetal Neonatal Ed. 2013;98:F437-9.
12. Demulder A, Ferster A, Pelc K, et al. Refractory status epilepticus and vacuolised bone marrow precursors: metabolic disease or treatment toxicity? J Pediatr Neurol. 2009;13:S127-8.
13. Fugate JE, Burns JD, Wijdicks EFM, Warner DO, Jankowski CJ, Rabinstein AA. Prolonged high-dose isoflurane for refractory status epilepticus: is it safe? Anesth Analg. 2010;110:1520-4.
14. Hilz MJ, Bauer J, Claus D, Stefan H, Neundorfer B. Isoflurane anesthesia in the treatment of nonconvulsive status epilepticus. J Neurol. 1992;239:135-7.
15. Hilz MJ, Erbguth F, Stefan H, Neundorfer B. Isoflurane for 7 days in refractory status epilepticus. Eur J Neurol. 1995;2:95-9.
16. Hughes DR, Sharpe MD, McLachlan RS. Control of epilepsia partialis continua and secondarily generalised status epilepticus with isoflurane. J Neurol Neurosurg Psychiatry. 1992;55:739-40.
17. Kofke WA, Snider MT, Young RSK, Ramer JC. Prolonged low flow isoflurane anesthesia for status epilepticus. Anesthesiology. 1985;62:653-6.
18. Kofke WA, Snider MT, O'Connell BK, et al. Isoflurane stops refractory seizures. Anesthesiology. 1987;67:A400.
19. Kofke WA, Young RSK, Davis P, et al. Isoflurane for refractory status epilepticus: a clinical series. Anesthesiology. 1989;71: 653-9.
20. Kofke WA, Bloom MJ, Van Cott A, Brenner RP. Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesth. 1997;9:269-72.
21. Lippert MM. Isoflurane anesthesia for status epilepticus. S Afr Med J. 1989;75:350.
22. Meeke RI, Soifer BE, Gelb AW. Isoflurane for the management of status epilepticus. DICP. 1989;23:579-81.
23. Savard M, Dupre N, Turgeon AF, Desbiens R, Langevin S, Brunet D. POLG mitochondrial disorder heralded by propofol infusion syndrome: a case report. Can J Neurol Sci. 2012;39(Suppl 3): G.09.
24. Mirsattari SM, Sharpe MD, Young B. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol. 2004;61:1254-9.
25. Robakis TK, Hirsch LJ. Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care. 2006;4:35-46.
26. Ropper AH, Kofke WA, Bromfield EB, Kennedy SK. Comparison of isoflurane, halothane, and nitrous oxide in status epilepticus. Ann Neurol. 1986;19:98-9.
27. Sakaki T, Abe K, Hoshida T, et al. Isoflurane in the management of status epilepticus after surgery for lesion around the motor area. Acta Neurochir (Wien). 1992;116:38-43.
28. Sharpe MD, Young GB, Mirsattari SM. Prolonged desflurane administration for refractory status epilepticus. Anesthesiology. 2002;97:261-4.
29. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. Available from: http: handbook.cochrane.org.
30. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
31. Phillips B, Ball C, Sackett D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-Based Medicine Levels of Evidence. Version 2009. Available from: http://www.cebm.net/?o=1025.
32. Guyatt GH, Oxman AD, Vist G, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
33. Guyatt GH, Oxman AD, Kunz R, et al. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-8.
34. Schünemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-10.
35. Guyatt GH, Oxman AD, Kunz R, et al. Rating quality of evidence and strength of recommendations: incorporating considerations of resources use into grading recommendations. BMJ. 2008;336: 1170-3.
36. Guyatt GH, Oxman AD, Kunz R, et al. Rating quality of evidence and strength of recommendations: going from evidence to recommendations. BMJ. 2008;336:1049-51.
37. Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ. 2008;337:a744.
38. Engelhard K, Werner C. Inhalational or intravenous anesthetics for craniotomies? Pro inhalational. Curr Opin Anesth. 2006;19:504-8.
39. Gibert S, Sabourdin N, Louvet N, et al. Epileptogenic effect of sevoflurane: determination of the minimal alveolar concentration of sevoflurane associated with major epileptoid signs in children. Anesthesiology. 2012;117:1253-61.
40. Iijima T, Nakamura Z, Iwao Y, Sankawa H. The epileptogenic properties of the volatile anesthetics sevoflurane and isoflurane in patients with epilepsy. Anesth Analg. 2000;91:989-95.
41. Voss LJ, Sleigh JW, Barnard JPM, Kirsch HE. The howling cortex: seizures and general anesthetic drugs. Anesth Analg. 2008;107: 1689-90.
42. Solt K, Eger EI, Raines DE. Differential modulation of human N-methyl-D-aspartate receptors by structurally diverse general anesthesia. Anesth Analg. 2006;102:1407-11.
43. Arici S, Karaman S, Dogru S, et al. Effects of isoflurane in an intoxication model: experimental study. Eur Rev Med Pharmacol Sci. 2013;17:1738-43.
44. Durak I, Oztürk HS, Dikmen B, et al. Isoflurane impairs antioxidant defence system in guinea pig kidney. Can J Anaesth. 1999;46: 797-802.
45. Filipovic M, Wang J, Michaux I, Hunziker P, Skarvan K, Seeberger MD. Effects of halothane, sevoflurane and propofol on left ventricular diastolic function in humans during spontaneous and mechanical ventilation. Br J Anaesth. 2005;94:186-92.
46. Marval P, Perrin ME, Hancock SM, Mahajan RP. The effects of propofol or sevoflurane on the estimated cerebral perfusion pressure and zero flow pressure. Anesth Analg. 2005;100:835-40.
47. Ding W, Li Z, Shen X, Martin J, King SB, Sivakumaran V, et al. Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca2+ . J Pharmacol Exp Ther. 2011;339:825-31.
48. Kopp VJ, Jobson M. Does isoflurane or isoflurane plus hyperoxia induce apoptotic cell death? Anesth Analg. 2013;117:1023.
49. Creeley CE, Dikranian KT, Dissen GA, Back SA, Olney JW, Brambrink AM. Isoflurane-induced apoptosis of neurons and oligodendrocytes in the fetal rhesus macaque brain. Anesthesiology. 2014;120:626-38.